CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
calcium +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000534
NCT00000534Phase 3Completed
CompareCT.gov

Calcium for Pre-Eclampsia Prevention (CPEP)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·interventional·Posted Oct 28, 1999·Updated Mar 13, 2017

In Brief

A Phase 3 clinical trial evaluating calcium and dietary supplements for Cardiovascular Diseases and 7 related conditions. Completed.

Detailed Summary

To evaluate the efficacy of 2 grams per day of oral calcium supplementation in reducing the combined incidence of hypertensive disorders of pregnancy: pre-eclampsia, eclampsia, and the HELLP Syndrome (hypertension, thrombocytopenia, hemolysis, and abnormal liver function). The National Institute of Child Health and Human Development (NICHD) initiated the trial in 1991, with joint funding provided by the National Heart, Lung, and Blood Institute in fiscal years 1992, 1993, and 1995.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases, Eclampsia, Heart Diseases, HELLP Syndrome, Hypertension, Pre-Eclampsia, Pregnancy Toxemias, Vascular Diseases
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 1999
Enrollment StartMar 1, 1991
Study CompletionJun 1, 2000
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

calciumdrug

dietary supplementsbehavioral